featured
FOLFIRI Plus Bevacizumab as Second-Line Therapy in Patients With Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology